Article
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
PloS one - 1 Jan 2021
González-Rincón Julia, Garcia-Vela José A, Gómez Sagrario, Fernández-Cuevas Belén, Nova-Gurumeta Sara, Pérez-Sanz Nuria, Alcoceba Miguel, González Marcos, Anguita Eduardo, López-Jiménez Javier, González-Barca Eva, Yáñez Lucrecia, Pérez-Persona Ernesto, de la Serna Javier, Fernández-Zarzoso Miguel, Deben Guillermo, Peñalver Francisco J, Fernández María C, de Oteyza Jaime Pérez, Andreu M Ángeles, Ruíz-Guinaldo M Ángeles, Paz-Arias Raquel, García-Malo M Dolores, Recasens Valle, Collado Rosa, Córdoba Raúl, Navarro-Matilla Belén, Sánchez-Beato Margarita, García-Marco José A
Abstract excerpt
Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.